Latest news

  • 21 May 2020

    Sensorion publishes results of General Assembly resolutions. Read

  • 29 April 2020

    Sensorion announces it will hold its General Assembly on May 20, 2020 behind closed doors alongside the publication of its 2019 annual financial report. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has one clinical stage drug candidate for sudden sensorineural hearing loss, two preclinical gene therapy programs and a cutting-edge inner ear R&D platform. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more